Quick Answer
Aldeyra Therapeutics, Inc. reported R&D Expense of $25.66 million for fiscal year 2025.
Aldeyra Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.66M | -46.8% |
| 2024 | $48.22M | +63.7% |
| 2023 | $29.46M | -37.7% |
| 2022 | $47.31M | +5.3% |
| 2021 | $44.94M | +82.1% |
| 2020 | $24.68M | -44.4% |
| 2019 | $44.35M | +48.7% |
| 2018 | $29.82M | +82.9% |
| 2017 | $16.30M | +23.7% |
| 2016 | $13.18M | +74.0% |
| 2015 | $7.57M | +104.3% |
| 2014 | $3.71M | +140.5% |
| 2013 | $1.54M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.43M | -56.3% | -36.1% |
| June 30, 2025 | $8.51M | -43.2% | +14.6% |
| March 31, 2025 | $7.42M | +20.1% | -40.3% |
| September 30, 2024 | $12.44M | +78.7% | -16.9% |
| June 30, 2024 | $14.97M | +115.0% | +142.1% |
| March 31, 2024 | $6.18M | -45.0% | -11.2% |
| September 30, 2023 | $6.96M | -39.7% | -0.0% |
| June 30, 2023 | $6.96M | -52.2% | -38.0% |
- Aldeyra Therapeutics, Inc. showed a decrease of -46.8% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Aldeyra Therapeutics, Inc.’s r&d expense has grown by 1564.6% (from $1.54 million to $25.66 million).
- The most recent figure is from Aldeyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: